

**NHS Foundation Trust** 

## Information Governance Department

Suite 9 Buckingham Row Brick Kiln Lane Wigan WN1 1XX

Email: foi@wwl.nhs.uk Web: www.wwl.nhs.uk

Ref: FOI/2024/10482

Date Received: 30th January 2025

Response Due: 27th February 2025

Date: 26<sup>th</sup> February 2025

## Dear Sir/Madam

With reference to your request for information received on 30<sup>th</sup> January 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do not hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

- 1. For patients treated by the dermatology department with Dupilumab in the latest four months (September to December 2024), could you please tell us:
  - a. how many patients were treated in the previous 4-month period (May to August 2024) with Dupilumab?
  - b. how many patients were treated in the previous 4-month period (May to August 2024) with any of the following advanced therapies: abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab?
  - c. how many patients were treated in the previous 4-month period (May to August 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?
  - d. how many patients were treated in the previous 4-month period (May to August 2024) with any other treatment? (e.g. Acitretin, Alitretoin, Pimecrolimus, Tacrolimus, oral corticosteroids, topical steroids)
- 2. For patients treated by the dermatology department with Dupilumab in the four months from May to August 2024, could you please let us:
  - a. how many patients were treated in the subsequent 4-month period (September to December 2024) with Dupilumab?
  - b. how many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following advanced therapies: abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab?

- c. how many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?
- d. how many patients were treated in the subsequent 4-month period (September to December 2024) with any other treatment? (e.g. Acitretin, Alitretoin, Pimecrolimus, Tacrolimus, oral corticosteroids, topical steroids)

The Trust is unable to provide this information. We are only able to provide data on patients that receive drugs in a certain period, but to then see what they had before/after that drug would require a manual trawl of patient records

Therefore, the Trust is unable to provide this data as it is not recorded centrally, if recorded it would be held within individual case notes. As case notes are for the care and treatment of patients, we do not request staff to interrogate them in order to collate the information required to respond to Freedom of Information requests.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

Master

Gary Masterman Deputy Chief Pharmacist

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire, SK9 5AF

Helpline number: 0303 123 111